Swedish biosimilars developer Xbrane Biopharma has revealed that it is dropping development of its planned Xtrudane pembrolizumab biosimilar to Keytruda, as part of a move towards a more “focused development portfolio.” At the same time, the firm has announced job cuts as part of a new cost-savings scheme designed to help the firm “achieve a positive cash flow as soon as possible.”

Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.

Xbrane and Stada have announced that they are seeking a new North American partner for their biosimilar ranibizumab candidate after agreeing to discontinue a deal with Bausch+Lomb.

Xbrane has announced the formal acceptance by the US FDA of its re-filed ranibizumab biosimilar, developed in collaboration with Stada and licensed in North America to Bausch + Lomb.